HeartFlow/$HTFL
1D1W1MYTD1Y5YMAX
Capital at risk
About HeartFlow
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
- Ticker
- $HTFL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 843
- Headquarters
- San Francisco, United States
- Website
- www.heartflow.com
HeartFlow Metrics
BasicAdvanced
$4.2B
-
-$1.54
-
-
Price and volume
Market cap
$4.2B
52-week high
$51.78
52-week low
$20.13
Average daily volume
2.1M
Financial strength
Current ratio
5.08
Quick ratio
4.657
Long term debt to equity
0.073
Total debt to equity
0.097
Interest coverage (TTM)
-21.02%
Profitability
EBITDA (TTM)
-71.355
Gross margin (TTM)
80.08%
Net profit margin (TTM)
-55.82%
Operating margin (TTM)
-34.31%
Effective tax rate (TTM)
0.08%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-18.05%
Return on equity (TTM)
-154.23%
Valuation
Price to revenue (TTM)
17.479
Price to book
14.97
Price to tangible book (TTM)
14.97
Price to free cash flow (TTM)
-62.634
Free cash flow yield (TTM)
-1.60%
Free cash flow per share (TTM)
-0.771
Growth
Revenue change (TTM)
42.77%
Earnings per share change (TTM)
-90.13%
What the Analysts think about HeartFlow
Analyst ratings (Buy, Hold, Sell) for HeartFlow stock.
Analyst projections of the future price of HeartFlow stock.
Bulls say / Bears say
Heartflow’s Q2 2026 revenue rose 48% year over year to $64.1 million, gross margin expanded to 83.0%, and management raised full-year revenue guidance to $246 million–$250 million, implying 40%–42% growth. (SEC)
Plaque Analysis offers a second growth engine alongside FFRCT: the company said CPT code 75577 became effective for Plaque reimbursement on January 1, 2026, while expanded coverage and account adoption are supporting commercialization. (SEC)
Recent clinical evidence could strengthen physician adoption and payer support: Heartflow reported that the independent FUSION trial presented in August 2026 showed FFRCT reduced unnecessary invasive heart procedures by nearly half. (Heartflow)
Heartflow remains unprofitable: Q2 2026 produced a $17.9 million operating loss and a $7.9 million non-GAAP operating loss, so continued growth still depends on scaling operating leverage and managing cash burn. (SEC)
Reimbursement remains a material execution risk. Heartflow’s latest annual filing warns that CMS or commercial-payor reductions could lower utilization, while coverage for Heartflow Plaque Analysis is still less established than for FFRCT. (SEC)
Competition is intensifying in AI-based coronary diagnostics, highlighted by Heartflow’s April 2026 patent lawsuit against rival Cleerly; the litigation could create legal costs, distraction, and uncertainty over the enforceability or scope of the company’s intellectual-property claims. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
HeartFlow Financial Performance
Revenues and expenses
HeartFlow Earnings Performance
Company profitability
Upcoming events
No upcoming events
HeartFlow News
AllArticlesVideos
Funds containing HeartFlow
AllEURGBPUSD
Fund name | Fund size | $HTFL weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.13% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.03% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.